Skip to main content
. 2009 Aug 27;37(19):6400–6413. doi: 10.1093/nar/gkp705

Figure 9.

Figure 9.

XRCC3 acts in the same pathway as ERCC1 in ICL repair. (A) Western blot showing knockdown of ERCC1, XRCC3 or ERCC1+XRCC3 in SQ20B cells. NT, non-targeting. β-Actin was used to control for loading. (B) The effects on clonogenic survival of knocking down ERCC1, XRCC3 or ERCC1+XRCC3 in SQ20B to cisplatin treatment. NT siRNA was used as negative control. Cisplatin was added to the dishes for 2 h before changing to drug-free medium. Graph indicates average and standard deviation of three to eight experiments.